Logo

Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen

Share this

Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen

Shots:

  • Coherus announces the Federal Circuit affirmation decision of the US District Court for the District of Delaware appealing that Coherus’ Udenyca (biosimilar- pegfilgrastim) does not infringe Amgen’s asserted patent 
  • On May 10- 2017 under BPCIA act- Amgen filled a patent infringement complaint against Coherus asserting US Patent 8-273-707 (“the ’707 patent”)- further in response Coherus filled lawsuit for dismissing the dispute. In Mar’18 the Delaware Court dismissed the whole case
  • Udenyca (pegfilgrastim-cbqv) is a s a PEGylated growth colony-stimulating factor targeted to decrease the incidence of infection- manifested by febrile neutropenia- in patients with non-myeloid malignancies myelosuppressive anti-cancer drugs

Click here to read full press release/ article | Ref: Coherus Biosciences| Image: SmarterAnalyst


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions